Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Funding, Business Update

4P-Pharma Announces Total Capital of ?15 Million Successfully Secured in Second Closing


4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from private investors.

With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model.

Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases."

This additional shareholders' financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.

This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma's startup studio model for building a balanced pipeline towards the commercial stage.

Revital Rattenbach concludes: "After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community."

About 4P-Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Site internet : https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma/

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.


These press releases may also interest you

at 05:06
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Digital Personalized Nutrition Market ? (By Purchase Model (Subscription, One Time Purchase), By End-users (Direct Consumers, Wellness & Fitness Centers,...

at 05:04
The global cell therapy market size is estimated to grow by USD 31041.49 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of 57.06% during the forecast period. ...

at 05:00
May 15, 2024 Amsterdam, the Netherlands ? Royal Philips , today announced that the exchange ratio for the dividend for the year 2023 is 1 new common share for every 29.2684 existing common shares. This ratio was based on the volume weighted average...

at 04:31
Allied Market Research published a report, titled, "Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue Heart Valve, and Transcatheter Heart Valve): Global Opportunity...

at 04:30
In industries like pharmaceuticals, food, and logistics, maintaining the integrity of products throughout the supply chain is critical. Temperature and humidity are two key parameters that can significantly affect the quality and safety of goods,...

at 04:25
Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a...



News published on and distributed by: